Brief: Acurx Announces First Patient Enrolled In Phase 2b Clinical Trial Of Its Lead Antibiotic For Treatment Of Clostridioides Difficile Infection
06/12/2021 14:33
Dec 6 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2B CLINICAL TRIAL OF ITS
LEAD
ANTIBIOTIC FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
Source text for Eikon: ID:nPn3JChdDa
Further company coverage: ACXP.O
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program